Çiftel Serpil, Tüzün Zeynep
Department of Endocrinology, Erzurum Training and Research Hospital, Erzurum, Türkiye.
Department of Internal Medicine, Rheumatology, Atatürk University, Faculty of Medicine, Erzurum, Türkiye.
Int J Gen Med. 2023 Apr 18;16:1375-1382. doi: 10.2147/IJGM.S406724. eCollection 2023.
Subacute thyroiditis (SAT) is a non-infectious inflammatory disease of the thyroid. The Systemic Immune-Inflammation Index (SII), also known as an easy economical marker, correlates with the severity of inflammatory responses. We aimed to evaluate the clinical significance of the SII and to compare it to other inflammatory markers in terms of diagnosis, recovery time, and recurrence of SAT.
The current non-interventional observational prospective study was performed at Outpatient Department of Endocrinology, Erzurum Training and Research Hospital. Sixty-nine patients with SAT and fifty-nine healthy individuals in total were enrolled in our study. The follow-up period was 6-12 months for all patients regarding treatment response, recurrence, and hypothyroidism.
The SII level was found to be significantly higher at the time of diagnosis in the SAT group compared to the control group (=0.000). There was a significant positive correlation between the SII and SAT recovery time (=0.000), particularly in patients receiving methyl prednisolone treatment (=0.002). SII was not found to be significantly associated with hypothyroidism and recurrence in patients with SAT (=0.261, =0.568). However, compared to the ones without recurrence, thyroid stimulating hormone (TSH) and erythrocyte sedimentation rate levels at the time of diagnosis were found to be higher in those patients with recurrence (=0.035, =0.046).
SII is a low-cost, widely available, universal indicator of inflammatory processes in SAT. It could provide many benefits in the follow-up process and the selection of aggressive anti-inflammatory treatment by estimating recovery time. SII, as a practical biomarker, may be a new diagnostic and prognostic tool for SAT.
亚急性甲状腺炎(SAT)是一种甲状腺的非感染性炎症性疾病。全身免疫炎症指数(SII),也被称为一种简便经济的标志物,与炎症反应的严重程度相关。我们旨在评估SII的临床意义,并在SAT的诊断、恢复时间和复发方面将其与其他炎症标志物进行比较。
本项非干预性观察性前瞻性研究在埃尔祖鲁姆培训与研究医院内分泌科门诊进行。我们的研究共纳入了69例SAT患者和59名健康个体。所有患者的随访期为6至12个月,内容涉及治疗反应、复发和甲状腺功能减退情况。
与对照组相比,SAT组在诊断时的SII水平显著更高(=0.000)。SII与SAT恢复时间之间存在显著正相关(=0.000),尤其是在接受甲泼尼龙治疗的患者中(=0.002)。未发现SII与SAT患者的甲状腺功能减退和复发有显著关联(=0.261,=0.568)。然而,与未复发的患者相比,复发患者在诊断时的促甲状腺激素(TSH)和红细胞沉降率水平更高(=0.035,=0.046)。
SII是SAT炎症过程的一种低成本、广泛可用的通用指标。通过估计恢复时间,它在随访过程和积极抗炎治疗的选择中可能会带来诸多益处。SII作为一种实用的生物标志物,可能是SAT的一种新的诊断和预后工具。